- Home
- IINN vs MTVA Comparison
IINN vs MTVA Comparison
Compare IINN & MTVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IINN
- MTVA
- Stock Information
- Founded
- IINN 2018
- MTVA 2014
- Country
- IINN Israel
- MTVA United States
- Employees
- IINN N/A
- MTVA N/A
- Industry
- IINN Medical/Dental Instruments
- MTVA
- Sector
- IINN Health Care
- MTVA
- Exchange
- IINN Nasdaq
- MTVA NYSE
- Market Cap
- IINN 13.7M
- MTVA 14.3M
- IPO Year
- IINN 2021
- MTVA N/A
- Fundamental
- Price
- IINN $0.85
- MTVA $0.66
- Analyst Decision
- IINN Strong Buy
- MTVA Strong Buy
- Analyst Count
- IINN 1
- MTVA 2
- Target Price
- IINN $2.00
- MTVA $7.50
- AVG Volume (30 Days)
- IINN 422.8K
- MTVA 133.9K
- Earning Date
- IINN 08-14-2025
- MTVA 08-13-2025
- Dividend Yield
- IINN N/A
- MTVA N/A
- EPS Growth
- IINN N/A
- MTVA N/A
- EPS
- IINN N/A
- MTVA N/A
- Revenue
- IINN N/A
- MTVA N/A
- Revenue This Year
- IINN N/A
- MTVA N/A
- Revenue Next Year
- IINN N/A
- MTVA N/A
- P/E Ratio
- IINN N/A
- MTVA N/A
- Revenue Growth
- IINN N/A
- MTVA N/A
- 52 Week Low
- IINN $0.40
- MTVA $0.63
- 52 Week High
- IINN $1.60
- MTVA $5.30
- Technical
- Relative Strength Index (RSI)
- IINN 63.38
- MTVA N/A
- Support Level
- IINN $0.70
- MTVA N/A
- Resistance Level
- IINN $0.77
- MTVA N/A
- Average True Range (ATR)
- IINN 0.06
- MTVA 0.00
- MACD
- IINN 0.01
- MTVA 0.00
- Stochastic Oscillator
- IINN 75.80
- MTVA 0.00
About IINN Inspira Technologies Oxy B.H.N. Ltd.
Inspira Technologies Oxy BHN Ltd is a specialty medical device company engaged in the research, development, manufacture, and marketing of proprietary respiratory support technology that is intended to provide an alternative to invasive mechanical ventilation (MV), which is the standard of care today for the treatment of respiratory failure. The respiratory care devices market is segmented geographically into North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.
About MTVA METAVIA INC
MetaVia Inc is a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat cardiometabolic diseases. It has two programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and obesity. DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and Type 2 Diabetes Mellitus (T2DM). DA-1726 is a novel oxyntomodulin (OXM) analogue functioning as a GLP-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist for the treatment of obesity that is designed to be administered once weekly subcutaneously.